



European Charcot Foundation

Co-ordination of Multiple Sclerosis Research in Europe

SYMPOSCIA

PROGRAMME EUROPEAN CHARCOT FOUNDATION SYMPOSIUM 2009

A new Treatment Era in Multiple Sclerosis Options, Challenges, Risks

November 12, 13 and 14, 2009

Lisbon, Portugal

Thursday November 12, 2009

XV European Charcot Foundation Lecture Trends in Treatment Strategies

M. Clanet

SESSION I

Pathology, pathophysiology and clinical application of new concepts

Pathophysiology of inflammation and tissue injury in MS: what are the targets for therapy?

H. Lassmann

New strategies in pathophysiology: on T-cell traffic and BBB

G. Comi

Clinical application of new concepts

G. Edan

Satellite Symposium I

Welcome Reception

Friday November 13, 2009 (morning)

Session II

Options, challenges and risks of new drugs

What to do in the Clinical Isolated Syndrome?

L. Kappos

What to do in fulminant Multiple Sclerosis?

P. Vermersch

The role of new drugs in the treatment of Relapsing Remitting Multiple Sclerosis

H.-P. Hartung

The role of new treatments in the progressive forms of Multiple Sclerosis: SPMS and PPMS

X. Montalban

Satellite Symposium II

Friday November 13, 2009 (afternoon)

Session III

Response measurement and how to use the tools.

MRI, CSF, Biomarkers, Pharmacogenomics.

How to evaluate the treatment response?

M. Freedman

The use of MRI in treatment response studies.

Markers for

F. Barkhof

inflammation, neuroprotection and repair

CSF and other Biomarkers. How to use them?

G. Giovannoni

The use of genome-wide association studies in treatment response?

A. Compston

Arguments for ending treatment - when and how?

K. Selmaj

Satellite Symposium III

Saturday November 14, 2009 (morning)

Session IV

Atypical syndromes

| | |
|---|--------------|
| On humeral immunological aspects in the brain of MS patients | E. Meinl |
| Neuromyelitis optica (NMO) and astrocytic damage in its pathogenesis | K. Fujihara |
| Sussac Syndrome, its diagnosis and treatment | X. Montalban |
| Acute inflammatory white matter disorders | J. Palace |
| Auto-antibodies to CNS proteins in children with first demyelinating event – implications for diagnosis and prognosis | B. Hemmer |

Saturday November 14, 2009 (afternoon)

Session V

The future

| | |
|--|-------------|
| Are there emerging treatments that promise to reduce progression of the disease? | J. Wolinsky |
| Patient autonomy in treatment choices | C. Heesen |

European Charcot Foundation Young Investigators Awards